-
2024-512733-32-00
5
2025-03-31
Acute Myeloid Leukemia (AML)
-
2023-505804-42-00
5
2024-07-10
NON SEGMENTAL VITILIGO
-
2023-503697-21-01
5
2024-06-24
Idiopathic pulmonary fibrosis
-
2023-507402-13-00
5
2024-04-03
Multiple myeloma
-
2022-502503-30-00
5
2022-12-15
Acute lymphoblastic leukemia
-
2024-516066-11-00
5
2022-08-31
Patients with newly diagnosed, histologically confirmed, primary advan
-
2023-506414-46-00
5
2022-04-22
High risk patients defined as having at least one of the following ris
-
2024-512972-36-00
9
2019-05-23
Indolent B-Cell Non-Hodgkin Lymphoma
-
2024-520138-31-00
4
2026-06-01
Early-stage favorable classic Hodgkin lymphoma
-
2025-524580-21-00
10
2026-06-01
Grass pollen induced allergic rhinitis or rhinoconjunctivitis
-
2022-501458-13-01
4
2026-04-29
Advanced Stage of Classic Hodgkin Lymphoma
-
2025-520466-22-00
5
2026-04-29
Advanced Platinum-resistant Epithelial Ovarian Cancer
-
2025-523717-29-00
5
2026-04-28
HFpEF or HFmrEF and obesity
-
2024-520014-22-00
5
2026-04-22
Locally advanced/metastatic urothelial carcinoma
-
2024-520101-39-00
5
2026-04-01
TROP2 NMR-positive advanced or metastatic non-squamous non-small cell
-
2025-521859-23-00
9
2026-03-31
PSMA-positive mCRPC with prior exposure to at least one prior ARPI
-
2025-522642-44-00
4
2026-03-18
CHRONIC SPONTANEOUS URTICARIA
-
2025-521762-99-00
5
2026-03-09
acute ischemic stroke
-
2025-521573-14-00
6
2026-03-04
Anthracycline-based antineoplastic therapy (standard of care/routine t
-
2024-516356-18-00
5
2026-02-17
Atherosclerotic cardiovascular disease (ASCVD)
-
2023-507879-21-00
4
2026-01-19
AML and MDS undergoing allogeneic Transplantation
-
2025-521144-38-00
4
2025-12-23
Primary Central Nervous System Lymphoma
-
2025-522860-34-00
5
2025-12-16
Small lymphocytic lymphoma (SLL)
-
2024-514500-14-00
5
2025-12-15
Participants with KRAS G12C-Mutant, Advanced or Metastatic Nonsquamous